Publications
Showing 501 to 510 of 555 Publications
| Title | Authors | Year | Journal |
|---|---|---|---|
| Amyloidogenic regions in beta-strands II and III modulate the aggregation and toxicity of SOD1 in living cells | McAlary L., Nan J.R., Shyu C., Sher M., Plotkin S.S*, & Cashman N.R* | 2024 | Open Biol |
| Amyloid ß Impacts Future Freezing of Gait in Parkinson’s Disease Via White Matter Hyperintensities | Dadar M, Miyasaki J, Duchesne S*, Camicioli R* | 2020 | bioRxiv |
| Amyloid beta plaque accumulation with longitudinal [18F]AZD4694 PET | Therriault, J.**, Lussier, F. Z., Tissot, C.**, Chamoun, M., Stevenson, J., Rahmouni, N.**, Pallen, V., Bezgin, G., Servaes, S., Kunach, P.**, Wang, Y. T.**, Fernandez-Arias, J.**, Vermeiren, M., Pascoal, T. A., Massarweh, G., Vitali, P., Soucy, J. P., Saha-Chaudhuri, P., Gauthier, S.*, & Rosa-Neto, P.* | 2023 | Alzheimer's & dementia |
| Alzheimer’s biomarkers from multiple modalities selectively discriminate clinical status: Relative importance of salivary metabolomics panels, genetic, lifestyle, cognitive, functional health and demographic risk markers | Sapkota, S., Huan, T., Tran T., Zheng, J., Camicioli, R., Li, L. & Dixon, R.A. | 2018 | Frontiers in Aging Neuroscience |
| Alzheimer’s environmental and genetic risk scores are differentially associated with general cognitive ability and dementia severity. | Andrews, S.J., McFall, G.P.**, Dixon, R.A.**, Cherbuin, N., Eramudugolla, R., Anstey, K.J. | 2019 | Alzheimer Disease & Associated Disorders |
| Alzheimer’s Disease Neuroimaging Initiative. Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer’s disease. | Pascoal T.A.**, Mathotaarachchi S.**, Shin M.**, Park A.Y., Mohades S., Benedet A.L.**, Kang M.S., Massarweh G., Soucy J.P.**, Gauthier S.**, Rosa-Neto P.** | 2018 | European Journal of Nuclear Medicine and Molecular Imaging |
| Alzheimer Disease, biomarkers, and clinical symptoms – Quo Vadis? | Montero-Odasso M*, Ismail Z*, Camicioli R* | 2020 | JAMA Neurology |
| Allocating Scarce Resources to Persons with Dementia During a Pandemic | Smith EE, Couillard P, Fisk JD, Ismail Z, Montero-Odasso M, Robillard J, Vedel I, Sivananthan S, Gauthier S. | 2020 | Canadian Geriatrics Journal |
| Agitation, Oxidative Stress, and Cytokines in Alzheimer Disease: Biomarker Analyses From a Clinical Trial With Nabilone for Agitation | Ruthirakuhan M, Herrmann N*, Andreazza AC, Verhoeff NPLG, Gallagher D, Black SE*, Kiss A, Lanctôt KL* | 2019 | Geriatr Psychiatry Neurol |
| Ageism and COVID-19: What does our society’s response say about us? | Fraser S*, Lagacé M, Bongué B, Ndeye N, Guyot J, Bechard L**, Garcia L, Taler V, CCNA Social Inclusion and Stigma Working Group, Adam S, Beaulieu M, Bergeron CD, Boudjemadi V, Desmette D, Donizzetti AR, Éthier S, Garon S, Gillis M, Levasseur M, Lortie-Lussier M, Marier P, Robitaille A, Sawchuk K, Lafontaine C, Tougas F. | 2020 | Age and Ageing |
Showing 501 to 510 of 555 Publications